Gas holdup time (tM) is a basic parameter in isothermal gas chromatography (GC). Determination and evaluation of tM and retention behaviors of n-alkanes under isothermal GC conditions have been extensively studied since the 1950s, but still remains unresolved. The difference equation (DE) model [J. Chromatogr. A 1260: 215-223] reveals retention behaviors of n-alkanes excluding tM, while the quadratic equation (QE) model [J. Chromatogr. A 1260: 224-231] including tM is suitable for applications. In the present study, tM values were calculated with the QE model, which is referred to as tMT, evaluated and compared with other three typical nonlinear models. The QE model gives an accurate estimation of tM in isothermal GC. The tMT values are highly accurate, stable, and easy to calculate and use. There is only one tMT value at each GC condition. The proper classification of tM values can clarify their disagreement and facilitate GC retention data standardization for which tMT values are promising reference tM values.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695472 | PMC |
http://dx.doi.org/10.1016/j.chroma.2013.04.078 | DOI Listing |
Alzheimers Dement
December 2024
University of California, Irvine, Irvine, CA, USA.
Background: In Alzheimer's disease (AD) clinical trials, participants must enroll with a study partner informant who accompanies them to visits and completes validated instruments. Mid-trial informant replacement (IR) has been found to impact academic trial results. We hypothesized that a similar impact would be observed in industry-sponsored trials.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of California, Irvine, Irvine, CA, USA.
Background: Amid recent approvals, early Alzheimer's disease (AD) remains an active area of treatment development, but research on the utility of recruitment incentives in early AD trials remains limited. We examined how trial design features impact enrollment decisions among Mild Cognitive Impairment (MCI) patients and their family members.
Method: We performed a conjoint analysis experiment to compare early AD patients' preferences for trial features.
Alzheimers Dement
December 2024
Indiana University School of Medicine, Indianapolis, IN, USA.
Background: Despite recognition of the need to increase underrepresented groups (URG) engagement in Alzheimer's disease and related dementias (ADRD) studies, enrollment remains low. As a first step in examining these disparities, these analyses aimed to compare referral sources for Alzheimer's Disease Research Centers (ADRC) enrollment of URG participants.
Method: These analyses included data from 48,330 participants across 46 ADRCs, obtained through the National Alzheimer's Coordinating Center Uniform Data Set.
Alzheimers Dement
December 2024
Prevent Alzheimer's Disease 2020, Inc., Rockville, MD, USA.
Background: With the changing care landscape for early Alzheimer's disease (AD), optimizing the diagnostic and management process is key. This study assessed the correlation between patient and physician characteristics and outcomes related to the diagnosis, referral, and treatment process for early AD in community-based settings.
Method: This cross-sectional study conducted between August and September 2023 abstracted medical chart data for patients aged 50-89 years who were diagnosed with early AD (mild cognitive impairment [MCI] or mild AD) within the past 2 years and had a clinic visit within the past year.
Alzheimer Dis Assoc Disord
January 2025
Departments of Psychiatry.
Introduction: Postoperative cognitive decline (POCD) is a common, but often unrecognized condition after surgery. We evaluate postsurgical cognitive changes in a longitudinal population-based study.
Methods: The study cohort comprises an age-stratified population-based random sample of individuals aged 65+ years from a small-town region of the United States.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!